Drugs / AGLE-102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05078385 | Aug 2023 → Sep 2024 | — | Aegle Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04173650 | Aug 2024 → Sep 2025 overdue | epidermolysis bullosa dystrophica | Aegle Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGLE-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05078385 ↗ |
| Modality | Other / unclassified | “AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs).” NCT04173650 ↗ |
| Route | Topical | “Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations” NCT04173650 ↗ |